Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Pembrolizumab may bring hope for patients with Hodgkin lymphoma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 3250

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Moskowitz talks to ecancertv at ASH 2014 about his recent phase I study of the PD-1 inhibitor pembrolizumab for the treatment of classical Hodgkin lymphoma. All patients in this study failed previous treatment with brentuximab vedotin, and the majority had relapsed after a stem cell transplant.

"Almost all of the patients responded to the treatment," he says. 

Read the news story and watch the press conference and a commentary here. 

ecancer's filming at ASH 2014 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation